| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RXRX | Class A Common Stock | Sale | $243,095 | -19,745 | -0.27% | $12.31 | 7,293,172 | 20 Feb 2024 | Direct | F1, F2 |
| transaction | RXRX | Class A Common Stock | Sale | $4,030 | -309 | -0% | $13.04 | 7,292,863 | 20 Feb 2024 | Direct | F1, F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023. |
| F2 | The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.97 to $12.96 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. |
| F3 | The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.98 to $13.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. |